Navigation Links
Novel Approach May Protect Against Heart Attack Injury
Date:7/10/2008

- Drugs Target Gene Pathways to Preserve Heart, Possibly Other Organs -

PHILADELPHIA, July 10 /PRNewswire-USNewswire/ -- Researchers at The Children's Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies. The finding has the potential to become an emergency treatment for heart attack patients, particularly since already existing drugs might be pressed into service to produce the protective effects.

"Reduced blood flow, or ischemia, is a major problem in many organs, where it can lead to cell death and tissue damage," said study leader Peter J. Gruber, M.D., Ph.D., a cardiothoracic surgeon at Children's Hospital and a faculty member of the University of Pennsylvania School of Medicine. "We decided to look for a global approach to protecting heart tissue by inhibiting enzymes that govern how cells respond to ischemia."

Gruber's team published their findings online July 7 in the journal of the Federation of American Societies for Experimental Biology (FASEB). The article will appear in the journal's October 2008 print issue.

The researchers made use of drugs called histone deactylase (HDAC) inhibitors that alter the way DNA is packaged within cells, as well as modifying the function of other proteins. Building on previous work by other researchers, who showed that HDAC inhibitors reduce ischemic injury in the brain, they used the same agents in mice with induced heart damage.

"We found significant and dramatic results in the mice," said Gruber. "The HDAC inhibitors reduced the area of tissue injury, even when delivered an hour after the ischemic event occurred." The size of the myocardial infarction--an area of dead tissue caused by obstructed blood flow, as occurs after a heart attack--was reduced by more than half.

In further investigating how the HDAC inhibitors acted, Gruber's team found they blocked gene pathways that led to cell death and ischemia-induced vascular permeability, the leakage of fluid through blood vessels. They also identified a specific molecule, HDAC4, as the likely HDAC enzyme with the most critical role in affecting how cells respond to ischemia.

An important advantage of their finding, said Gruber, is that a number of HDAC inhibitors are already used in medicine, for treating both cancer and epilepsy, and are well-tolerated. Although much research remains to be done, he added, this raises the possibility that existing drugs, or modified versions of them, might play an important new role in heart disease.

Because the protective effect of HDAC inhibitors may occur even after the initial blockage of blood flow, therapies based on Gruber's research may lead to an emergency treatment following a heart attack. In addition, because open-heart surgery for both children and adults requires a period in which the heart is stopped, such treatment might also protect tissues from the adverse effects of interrupting blood flow during surgery.

For now, said Gruber, the next step for his study team will be to test how HDAC inhibitors work in protecting against ischemic injury in larger animals.

A National Institutes of Health grant partially supported the research, in addition to funding from the McCabe Foundation, the University Research Foundation and the Division of Pediatric Cardiothoracic Surgery at The Children's Hospital of Philadelphia.

Gruber's co-authors were Anne Granger, Ibrahim Abdullah, Faith Huebner, and Thomas Huebner, of Children's Hospital; and Jonathan A. Epstein, M.D., of the University of Pennsylvania School of Medicine. Gruber, Granger, and co-authors Andrea Stout and Tao Wang are members of the Penn Cardiovascular Institute, of which Epstein is the scientific director.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

Contact: John Ascenzi

Phone: (267) 426-6055

Ascenzi@email.chop.edu


'/>"/>
SOURCE The Children's Hospital of Philadelphia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
2. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
3. DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
4. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
5. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
6. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
7. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
10. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
11. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. ... appointed Paul M. Bisaro as Impax,s President ... Company,s Board, effective March 27, 2017. Mr. Bisaro will ... as Interim President and Chief Executive Officer since December ... generic and branded pharmaceutical experience, Mr. Bisaro, 56, is ...
(Date:3/27/2017)... 2017 Invivotek, LLC, a Genesis Biotechnology Group ... pharmacology contract research organization (CRO), announced the completion ... expanded preclinical research facility in Hamilton, New ... renewable energy source to reduce costs and lessen the ... Genesis Solar Farm follows Invivotek,s recent expansion from a ...
(Date:3/24/2017)... , March 24, 2017  Zymo Research ... and Hamilton Robotics, Inc., who designs, manufactures ... ongoing collaboration that teams Zymo Research,s DNA ... and DNA extraction products with Hamilton,s high-throughput ... optimized methods for microbiomics and RNA isolation ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to 2015, ... for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat the ... proposes a tax on prescription opioids to fund drug rehabilitation and prevention services.(3) ...
(Date:3/26/2017)... ... March 26, 2017 , ... ... receive the RealSelf 100 Award, a prestigious award honoring the top influencers on ... to find and connect with doctors and clinics. , In 2016, more than ...
(Date:3/24/2017)... ... March 24, 2017 , ... Clean Earth, Inc., ... and hazardous and non-hazardous materials announced today the acquisition of privately owned ... add four additional processing facilities and a vast array of additional technologies, services, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA Senior ... not obey the rules Congress has directed the CBO to follow. The CBO itself ... would restore. Yet, it estimates a reduction in employer-based coverage due to the GOP ...
Breaking Medicine News(10 mins):